Vir Biotechnology Secures $240M Upfront in Astellas Prostate Cancer Deal — Vir Biotechnology, Inc.

Event summary

Vir Biotechnology closed a global collaboration with Astellas for VIR-5500, a PSMA-targeted T-cell engager for metastatic prostate cancer, on April 16, 2026.
The deal includes a $240M upfront payment, a $75M equity investment at $10.36 per share, and up to $1.37B in potential milestones.
Vir will share U.S. profits equally with Astellas and receive tiered, double-digit royalties on ex-U.S. sales.
VIR-5500 is the only dual-masked PSMA-targeting TCE in clinical evaluation, currently in a Phase 1 trial for mCRPC.

The big picture

This deal underscores the growing focus on targeted immunotherapies for prostate cancer, particularly T-cell engagers with reduced toxicity profiles. Vir's PRO-XTEN® masking technology positions it as a key player in the space, though it must navigate competitive pressures and clinical risks to realize the collaboration's full potential. The $240M upfront payment and potential $1.37B in milestones highlight the high stakes in oncology partnerships.

What we're watching

Clinical Progress: How the Phase 1 trial data for VIR-5500 will shape its development timeline and regulatory path.
Financial Impact: Whether Vir can sustain its growth trajectory with the upfront payment and potential milestone revenues.
Competitive Dynamics: The pace at which competitors develop similar PSMA-targeting therapies for prostate cancer.